Workflow
Canature Health(300272)
icon
Search documents
开能健康:截至2025年9月30日公司股东总户数为21993户
Zheng Quan Ri Bao Wang· 2025-10-10 07:43
证券日报网讯开能健康(300272)10月10日在互动平台回答投资者提问时表示,截至2025年9月30日, 公司股东总户数为21,993户。 ...
开能健康(300272) - 关于选举职工代表董事的公告
2025-09-29 11:12
开能健康科技集团股份有限公司 关于选举产生第六届董事会职工代表董事的公告 本公司及董事会全体成员保证公告内容真实、准确和完整,不存在虚假记 载、误导性陈述或者重大遗漏。 一、选举第六届董事会职工代表董事的情况 证券代码:300272 证券简称:开能健康 公告编号:2025-084 JINFENG(金凤)女士符合《公司法》《深圳证券交易所上市公司自律监管 指引第2号——创业板上市公司规范运作》《公司章程》规定的有关职工代表董事 任职资格。JINFENG(金凤)女士担任公司职工代表董事后,公司第六届董事会 中兼任公司高级管理人员的董事以及由职工代表担任的董事人数总计未超过董 事总数的二分之一,符合相关法律法规的要求。 二、备查文件 附件: 开能健康科技集团股份有限公司 开能健康科技集团股份有限公司(以下简称"公司 "或"本公司")于2025 年9月10日召开的第六届董事会第二十六次会议审议通过了《关于修订<公司章 程>并变更公司注册资本的议案》以及《关于修订公司部分制度的议案》。根据中 国证券监督管理委员会发布的《关于新<公司法>配套制度规则实施相关过渡期 安排》《上市公司章程指引》等相关法律法规的规定,结合实际 ...
开能健康(300272) - 2025年第二次临时股东大会决议公告
2025-09-29 11:12
证券代码:300272 证券简称:开能健康 公告编号:2025-083 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、 误导性陈述或者重大遗漏。 特别提示 1、本次股东大会召开期间没有增加、否决或者变更议案的情况发生; 2、本次股东大会不存在变更前次股东大会决议的情形。 一、会议的召开和出席情况 (一)会议召开情况 通过深交所交易系统进行网络投票的时间为2025年9月29日9:15-9:25、9:30-11:30 和13:00-15:00; 通过互联网投票系统投票的时间为2025年9月29日上午9:15-下午15:00期间任意时 间。 1、会议召开的时间 (1)现场会议时间:2025年9月29日下午2:30开始 (2)网络投票时间: 1.00《关于修订<公司章程>并变更公司注册资本的议案》; | | 参加表决股数 | 赞成股数(股) | 比例 | 反对股数 | 比例(%) | 弃权股数 | 比例 | | --- | --- | --- | --- | --- | --- | --- | --- | | | (股) | | (%) | (股) | | (股) | (%) | | 总体表 ...
开能健康(300272) - 国浩律师(上海)事务所关于开能健康2025年第二次临时股东大会法律意见书
2025-09-29 11:12
国浩律师(上海)事务所 临时股东大会法律意见书 国浩律师(上海)事务所 Grandall Law Firm (Shanghai) 中国 上海 山西北路 99 号苏河湾中心 25-28 楼,200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Shanghai 200085, China 电话/TEL.: (+86)(21) 5234 1668 传真/FAX: (+86)(21) 5243 3320 国浩律师(上海)事务所 关于开能健康科技集团股份有限公司 2025 年第二次临时股东大会的 法律意见书 致:开能健康科技集团股份有限公司 根据出席现场会议股东的签名及授权委托书,出席现场会议的股东及股东代 表 15 人,代表公司股份 151,216,952 股,占公司有表决权股份总数的 27.1417%。 根据《中华人民共和国公司法》(以下简称"《公司法》")《中华人民共和国 证券法》(以下简称"《证券法》")和《上市公司股东会规则》(以下简称"《股东 会规则》")的规定,国浩律师(上海)事务所(以下简称"本所")接受开能健 康科技集团股份有限公司(以下简称"公司") ...
小家电板块9月29日跌0.42%,新宝股份领跌,主力资金净流出1944.98万元
Market Overview - The small home appliance sector experienced a decline of 0.42% on September 29, with Xinbao Co., Ltd. leading the drop [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] Stock Performance - Notable gainers in the small home appliance sector included: - Biyi Co., Ltd. (603215) with a closing price of 22.38, up 3.90% and a trading volume of 185,400 shares, totaling 422 million yuan [1] - ST Dehao (002005) closed at 2.40, up 3.45% with a trading volume of 168,000 shares, totaling 40.13 million yuan [1] - Major decliners included: - Xinbao Co., Ltd. (002705) with a closing price of 15.69, down 1.81% and a trading volume of 85,200 shares, totaling 133 million yuan [2] - Supor (002032) closed at 47.79, down 1.40% with a trading volume of 19,900 shares, totaling 95.41 million yuan [2] Capital Flow - The small home appliance sector saw a net outflow of 19.45 million yuan from institutional investors, while retail investors experienced a net outflow of 8.96 million yuan [2] - Conversely, speculative funds recorded a net inflow of 28.41 million yuan [2] Individual Stock Capital Flow - Biyi Co., Ltd. (603215) had a net outflow of 29.01 million yuan from institutional investors, with a net inflow of 10.83 million yuan from speculative funds [3] - Covos (603486) saw a net inflow of 17.62 million yuan from institutional investors, while retail investors had a net outflow of 15.22 million yuan [3] - Other notable stocks included: - ST Dehao (002005) with a net inflow of 3.48 million yuan from institutional investors [3] - Kaineng Health (300272) with a net inflow of 3.47 million yuan from institutional investors [3]
开能健康半年营收8.89亿增7.23% 拟投1亿设全资子公司布局细胞产业
Chang Jiang Shang Bao· 2025-09-28 23:06
Core Viewpoint - The company, Kaineng Health, is entering the cell industry by establishing a wholly-owned subsidiary, Kaineng Cell Medical Group, with an investment of 100 million yuan, aiming to create a second growth curve through this strategic move [1][2]. Group 1: Business Expansion - Kaineng Health plans to focus on the cell and biotechnology sectors, covering areas such as medical aesthetics, medical research, drug clinical trials, and cosmetics production and sales [1][2]. - The establishment of the new subsidiary is part of the company's "dual energy drive" development strategy, aimed at strengthening its position in the cell industry and expanding its business footprint [2]. Group 2: Financial Performance - In the first half of 2025, Kaineng Health reported a revenue of 889 million yuan, a year-on-year increase of 7.23%, and a net profit attributable to shareholders of 70.15 million yuan, up 22.99% [1][2]. - The company's gross profit margin reached 41.12%, an increase of 0.62 percentage points compared to the same period last year, driven by improved production efficiency [2]. Group 3: Global Strategy - Kaineng Health is actively pursuing a "going global" strategy, establishing a comprehensive ecosystem and global layout across key markets in North America, Europe, and Asia-Pacific [3]. - The company has successfully expanded its water treatment products into over 100 countries and regions, with its Canadian subsidiary, Canature N.A.Inc., achieving a net profit of 23.97 million yuan in the reporting period [3]. Group 4: Industry Potential - The global cell therapy market is projected to exceed 30 billion USD by 2025, with a compound annual growth rate of over 20%, indicating significant growth potential for the company [4]. - Kaineng Health aims to leverage its existing water treatment business and the advantages of its partner, Yuaneng Group, in the cell industry to achieve synergistic development [5].
开能健康(300272):点评:打造细胞产业为公司第二曲线,主业稳健增长
上 市 公 司 家用电器 | 基础数据: | 2025 年 06 月 30 日 | | --- | --- | | 每股净资产(元) | 2.07 | | 资产负债率% | 56.53 | | 总股本/流通 A 股(百万) | 611/464 | | 流通 B 股/H 股(百万) | -/- | 一年内股价与大盘对比走势: 09-24 10-24 11-24 12-24 01-24 02-24 03-24 04-24 05-24 06-24 07-24 08-24 09-24 0% 10% 20% 30% 40% 开能健康 沪深300指数 (收益率) 相关研究 证券分析师 刘正 A0230518100001 liuzheng@swsresearch.com 刘嘉玲 A0230522120003 liujl@swsresearch.com 2025 年 09 月 25 日 开能健康 (300272) ——点评:打造细胞产业为公司第二曲线,主业稳健增长 报告原因:有信息公布需要点评 增持(维持) | 市场数据: | 2025 年 09 月 24 日 | | --- | --- | | 收盘价(元) | 6.46 ...
公告精选︱皖维高新:前三季度净利润预增69.81%到109.77%;华软科技:现有光引发剂产品,按客户订单小批量生产销售
Ge Long Hui· 2025-09-25 00:09
Key Points - Huasoft Technology is currently producing and selling light initiator products in small batches based on customer orders [1] - Kaineng Health plans to establish a wholly-owned subsidiary in Hainan or Hunan provinces to engage in the cell industry and related mergers and acquisitions [1] - Linyang Energy has won a bid for a 142 million yuan project with the State Grid [1] - New Zhizhi Software intends to acquire 49% equity of Shenzhen Hengdao for 48.2356 million yuan [1] - Xindian Software plans to repurchase shares worth between 30 million to 50 million yuan [1] - Shanjin International has submitted an application for the issuance and listing of H-shares on the Hong Kong Stock Exchange [1] - Zhongwei Semiconductor has also submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [1] - Huadong Heavy Machinery's Wu Qingming Yu No. 6 and Tianchen Jinting No. 1 plan to reduce their holdings by no more than 1.5% [2] - Xinde New Materials' Shang Rong Baoying and its concerted parties plan to reduce their holdings by no more than 3% [2] - Huayi Pharmaceutical's shareholder Wang Xiaopeng plans to reduce his holdings by no more than 12.708 million shares [2] - International Industry plans to raise no more than 660 million yuan through a private placement to its controlling shareholder [2] - Ruima Precision has been awarded a project for automotive air suspension system products [2] - Wanhui High-tech expects a net profit increase of 69.81% to 109.77% for the first three quarters [2]
开能健康:关于对外投资设立全资子公司的公告
(编辑 任世碧) 证券日报网讯 9月24日晚间,开能健康发布公告称,根据公司双能驱动的长期战略规划,公司拟以自有 资金在海南省或湖南省等地区设立全资子公司从事细胞行业业务(最终以工商登记为准)及行业并购事 宜,全资子公司注册资本为10,000万元人民币。本次交易在总经理审批权限范围内,无需提交董事会 审议。 ...
开能健康(300272.SZ):拟在海南省或湖南省等地区设立全资子公司从事细胞行业业务及行业并购事宜
Ge Long Hui A P P· 2025-09-24 08:04
格隆汇9月24日丨开能健康(300272.SZ)公布,根据公司双能驱动的长期战略规划,公司拟以自有资金在 海南省或湖南省等地区设立全资子公司从事细胞行业业务(最终以工商登记为准)及行业并购事宜,全 资子公司注册资本为10,000万元人民币。 ...